Sakaorat LertjuthapornClaudia CicalaDonald Van RykMatthew LiuJason YolitzDanlan WeiFatima NawazAllison DoyleBrooke HorowitchChung ParkShan LuYang LouShixia WangRuimin PanXunqing JiangFrancois VillingerSiddappa N. ByrareddyPhilip J. SantangeloLynn MorrisConstantinos Kurt WibmerKristin BirisRosemarie D. MasonJason GormanJoseph HiattElena MartinelliMario RoedererDai FujikawaGiacomo GoriniGenoveffa FranchiniAnush ArakelyanAftab A. AnsariKovit PattanapanyasatXiang Peng KongAnthony S. FauciJames ArthosCentre for the AIDS Programme of Research in South AfricaNational Institute for Communicable DiseasesNYU School of MedicineUniversity of California, San FranciscoPopulation Council HeadquartersNew Iberia Research CenterGeorgia Institute of TechnologyNational Institute of Child Health and Human DevelopmentNational Institute of Allergy and Infectious DiseasesUniversity of Nebraska Medical CenterUniversity of WitwatersrandNational Cancer InstituteFaculty of Medicine, Siriraj Hospital, Mahidol UniversityEmory University School of MedicineUniversity of Massachusetts Medical School2019-08-232019-08-232018-08-01PLoS Pathogens. Vol.14, No.8 (2018)15537374155373662-s2.0-85053086140https://repository.li.mahidol.ac.th/handle/20.500.14594/45102© 2018, Public Library of Science. All rights reserved. The GI tract is preferentially targeted during acute/early HIV-1 infection. Consequent damage to the gut plays a central role in HIV pathogenesis. The basis for preferential targeting of gut tissues is not well defined. Recombinant proteins and synthetic peptides derived from HIV and SIV gp120 bind directly to integrin α4β7, a gut-homing receptor. Using both cell-surface expressed α4β7and a soluble α4β7heterodimer we demonstrate that its specific affinity for gp120 is similar to its affinity for MAdCAM (its natural ligand). The gp120 V2 domain preferentially engages extended forms of α4β7in a cation -sensitive manner and is inhibited by soluble MAdCAM. Thus, V2 mimics MAdCAM in the way that it binds to α4β7, providing HIV a potential mechanism to discriminate between functionally distinct subsets of lymphocytes, including those with gut-homing potential. Furthermore, α4β7antagonists developed for the treatment of inflammatory bowel diseases, block V2 binding to α4β7. A 15-amino acid V2 -derived peptide is sufficient to mediate binding to α4β7. It includes the canonical LDV/I α4β7binding site, a cryptic epitope that lies 7–9 amino acids amino terminal to the LDV/I, and residues K169 and I181. These two residues were identified in a sieve analysis of the RV144 vaccine trial as sites of vaccine -mediated immune pressure. HIV and SIV V2 mAbs elicited by both vaccination and infection that recognize this peptide block V2-α4β7interactions. These mAbs recognize conformations absent from the β- barrel presented in a stabilized HIV SOSIP gp120/41 trimer. The mimicry of MAdCAM-α4β7interactions by V2 may influence early events in HIV infection, particularly the rapid seeding of gut tissues, and supports the view that HIV replication in gut tissue is a central feature of HIV pathogenesis.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyArticleSCOPUS10.1371/journal.ppat.1007278